Chinese Genome-Based Drug Market Analysed & Forecast by AMID in New Study Published at

22 Jun 2015 • by Natalie Aster

LONDON – During the last 10 years, China has witnessed mushrooming growth in demand for genome-based drugs. In the years to come, production and demand alike are projected to keep on increasing. The national economy keeps on witnessing a burgeoning growth, which has been propelled by the ensuing increases in industrial output, imports and exports, capital investments and consumers’ consumption for more than 20 years.

New research study “Genome-Based Drug Markets in China” drawn up by Asia Market Information & Development Co (AMID) offers an unrivalled guide to the Chinese marketplace for genome-based drugs. The research report presents an in-depth analysis of the nation’s economic trends, investment landscape, the industry’s structure and evolution, demand and supply dynamics, industry capacity, and the various marketing channels. It canvasses the competitive scenario in tandem with an examination of the most prominent industry players. Historical figures are provided for the years 2004, 2009 and 2014; as well as granular long-term forecasts are available through to 2019 and till 2024. Furthermore, the research publication provides detailed profiles of the country’s leading manufacturers.

Report Details:

Genome-Based Drug Markets in China
Published: June, 2015
Pages: 212 
Price: US$ 4,000.00

More reports by the publisher can be found at AMID page.


The Market Publishers, Ltd.
Natalie Aster
Tel: +44 208 144 6009
Fax: +44 207 900 3970